Description: Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HCV. Phase 1b studies in HCV infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 4 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 60% of the Company, including the Frost Group. OPKO Health, Inc., Brace Pharma Capital, LLC and Teva Pharmaceuticals Industries, Ltd. are corporate investors.
Home Page: www.cocrystalpharma.com
COCP Technical Analysis
19805 North Creek Parkway
Bothell,
WA
98011
United States
Phone:
786 459 1831
Officers
| Name | Title |
|---|---|
| Dr. Roger D. Kornberg Ph.D. | Co-Founder, Chairman, Chief Scientist & Chairman of Scientific Advisory Board |
| Dr. Sam Lee Ph.D. | Co-Founder, Interim Co-CEO & Pres |
| Mr. James J. Martin CPA, CPA, M.B.A., MBA | Interim Co-CEO, CFO & Corp. Sec. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4525 |
| Price-to-Sales TTM: | 92.4548 |
| IPO Date: | 2011-05-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 13 |